english.prescrire.org > Prescrire International > N°214 - April 2020

n°214

April 2020

Issue Contents
Editorial

Free  New drugs: the right to know

p.87

Marketing Authorisations

Trientine (Cufence°, Cuprior°) and Wilson's disease

p.89-91
An option when penicillamine is poorly tolerated

Velmanase alfa (Lamzede°) in mild to moderate alpha-mannosidosis

p.91-93
Possible clinical improvement?

Semaglutide (Ozempic°) and type 2 diabetes

p.93

Standardised ragweed pollen allergen extract (Ragwizax°) and allergic rhinitis

p.93

Dequalinium chloride vaginal tablets (Vablys°) and bacterial vaginosis

p.94

Free  Denosumab (Prolia°) and steroid-induced osteo­por­osis

p.95

Free  Editors' opinion. EMA turns a blind eye to denosumab's lack of proven clinical efficacy

p.96

Adverse Effects

Lithium during pregnancy: malformations, fetotoxicity and uncertain long-term effects

p.97-99

Ticagrelor: dyspnoea and sleep apnoea

p.99

Adverse effects of radiopharmaceuticals in France

p.100-101

Alizapride: authorisation withdrawn for use in children

p.102

Polystyrene sulfonate: intestinal obstruction, necrosis and perforation

p.102-103

Pregabalin: suicides

p.103-104

SSRI antidepressants: compulsive buying, pathological gambling

p.104

Reviews

Rapid diagnostic tests and acute pharyngitis

p.105-106
Mainly useful to rule out group A streptococcal infection

Omega-3 fatty acids after myocardial infarction: authorisations revoked in the European Union

p.106

Outlook

Free  Zolgensma°: the drug of extremes

p.107

Free  France's Mediator° disaster: creating awareness around conflicts of interest

p.108-109

Free  Drugs in 2019: a brief review

p.110-111

Masthead

Free  Masthead

p.86

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe